Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Benazepril and its active metabolite benazeprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension and heart failure. Oral administration every 12-24 hours.
It is excreted in breastmilk in clinically insignificant amounts. (AEMPS 2017, FDA 2015, Frank 2004, Shannon 2000, Kaiser 1989)
No problems have been observed in infants whose mothers were taking other ACEIs (Anderson 2018).
Expert authors consider the use of this drug acceptable during breastfeeding (Hale, LactMed, Briggs 2015).
Due to its potential renal toxicity in premature infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015)
The protective role of breastfeeding against maternal hypertension has been proven. (Park 2018)